Clinical Trial Search

Primary: PFS Rate — 54.6 percentage of patients

Primary: Confirmed Response Rate (CR or PR) Using RECIST — 0 percentage of participants

Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks

Primary: Progression Free Survival of Patients With Unresectable Angiosarcoma — 4.2; 4.3; 3.5; 2.9 months

Primary: Progression-Free Survival (PFS) at 4 Months — 52.17 percentage of patients alive

Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants

Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Overall Objective Response — 1; 21; 26 participants

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Tumor Best Response Rate — 0 Participants

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 3; 1; 22 Participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants

Primary: Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months — 81.8 percentage of participants

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Overall Survival (OS) — 13.73; 13.14 Months